What is SNDX's current stock price?

SNDX (Syndax Pharmaceuticals, Inc.) is currently trading at $19.94 with a market cap of $1.77B.

What sector is Syndax Pharmaceuticals, Inc. in?

Syndax Pharmaceuticals, Inc. (SNDX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is SNDX a good stock to buy?

Analysts have a Buy consensus on SNDX with a price target of $41.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

SNDX Syndax Pharmaceuticals, Inc.

Healthcare

$19.94+0.86%ClosedMarket Cap: $1.77B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

41.50

P/S

8.14

EV/EBITDA

-12.19

DCF Value

$14.13

FCF Yield

-15.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

98.0%

Operating Margin

-102.9%

Net Margin

-112.0%

ROE

-256.7%

ROA

-51.5%

ROIC

-57.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$64.9M	$-42.7M	$—
Q4 null	$68.5M	$-68.0M	$—
FY null	$172.4M	$-285.4M	$—
Q3 null	$45.9M	$-60.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$41.50

Target (Median)

$41.50

Target Range

$37.00 - $46.00

2 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-22

UBSBuy

2026-05-13

BarclaysOverweight

2026-05-01

Goldman SachsBuy

2026-04-01

MizuhoOutperform

2026-03-31

Trading Activity

Insider Trades

View All

Metzger Michael Adirector, officer: Chief Executive Officer

SellTue Feb 10

Goldan Keith A.officer: Chief Financial Officer

SellTue Feb 10

Metzger Michael Adirector, officer: Chief Executive Officer

SellFri Feb 06

Metzger Michael Adirector, officer: Chief Executive Officer

SellFri Feb 06

Metzger Michael Adirector, officer: Chief Executive Officer

SellFri Feb 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.41

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Peers